FDA Approves Ecstasy Clinical Trial To Treat PTSD
C. J. Hardin toured Iraq and Afghanistan three times, which gave him post-traumatic stress disorder. He had tried almost all acceptable treatments for PTSD.
"Nothing worked for me, so I put aside the idea that I could get better. I just pretty much became a hermit in my cabin and never went out," Hardin said.
In 2013, he joined a small drug testing trial for Methylenedioxy methamphetamine (MDMA) as PTSD treatment, and Hardin said the trial helped him. "It changed my life. It allowed me to see my trauma without fear or hesitation and finally process things and move forward."
FDA Approved Clinical Trial To Test MDMA Effectiveness On PTSD
Illegal party drug Methylenedioxy methamphetamine (MDMA), better known as ecstasy, has been approved by the Food and Drug Administration to be used in a Phase 3 clinical trial to treat people with PTSD, based on the result story of people like Hardin. If the trial is successful, it could mean a final step for the possible approval of Ecstasy as a prescription drug.
Research has shown that ecstasy uses causes the brain to flood hormones and neurotransmitters that evoke feelings of trust and well-being, while muting fear and negative emotions. Patients said using ecstasy during the trial gave them clarity and the ability to address their problems.
Dr. Charles R. Marmar, the head of psychiatry at New York University's Langone School of Medicine, a leading PTSD researcher who was not involved in the study, said: "I'm cautious but hopeful. If they can keep getting good results, it will be of great use. PTSD can be very hard to treat. Our best therapies right now don't help 30 to 40 percent of people. So we need more options."
Some Experts Raise Concerns Over The Approval
Othe scientists worry that FDA's move could encourage people to use the drug recreationally, even in controlled circumstances. Andrew Parrott, a psychologist at Swansea University in Wales who has studied the brains of chronic Ecstasy users said: "It sends the message that this drug will help you solve your problems, when often it just creates problems. This is a messy drug we know can do damage."
The clinical trial for ecstasy will involve at least 230 patients, and if the results continue to be promising, the drug could be used for PTSD treatment in 2021.
President Trump Nominates Conservative Physician, Scott Gottlieb, To Head the FDA
President Donald Trump has nominated Dr. Scott Gottlieb as potential had of the US Food and Drug Administration (FDA) agency. Gottlieb is regarded as a conservative physician and businessman with extensive experience of how the pharmaceutical industry is run. In fact, many voices in the health industry call for the US Senate to approve his nomination for the job.
Nasal Irrigation Pots Increase Risk For Brain-Eating Amoebas
The FDA have issued a health warning to those who use nasal irrigation pots, or Neti pots, to make sure that they use distilled water, or even boil the water first, to avoid infections. The warning came after some reports of brain-eating amoeba surfaced not long ago during the flu season.
Ketamine Shows Promising Results To Treat PTSD
As PTSD is starting to become a trend not just in soldiers, what role does ketamine play to treat this condition? Can it be taken by just anyone who’s suffering from the said disorder? What’s the truth behind claims that ketamine is the key for PTSD? Find out what experts have to say
Brexit May Delay Cancer Drugs For Two Years
Health authorities are concerned that Brexit may delay the availability of important new drugs, including cancer drugs, for up to two years. It may also increase the prices of medicines that patients would have to pay.
FDA Approves Emflaza as Drug for Treating Muscular Dystrophy
The US Food and Drug Administration (FDA) has approved the use of deflazacort, marketed under the brand name Emflaza, for the treatment of Duchenne muscular dystrophy (DMD) in children. The steroid drug is manufactured by Marathon Pharmaceuticals and is the first to be so approved by the FDA to treat people with the condition in the United States.
MORE IN ITECHPOST
'Tokyo Ghoul' Season 3 Delayed By Its Live-Action Movie? Ken Kenaki Returns With Another Identity?
"Tokyo Ghoul" season 3's release is delayed and there are countless speculations as to why it is being pushed back. Reports claim that the show is to give way to "One Punch Man" and "My Hero Acdemia" but new rumors say that it's lack of materials and storyline as well as its live-action movie are causing the delay.